The Smiths Falls-based producer saw its consolidated net revenue reach 71.2 million Canadian dollars for the quarter ending March 31. Growth was powered primarily by the domestic market, where medical cannabis sales climbed 27 percent and adult-use products eked out a 1 percent gain. This performance offset a 14 percent decline in the vaporizer division, Storz & Bickel, which generated 16.8 million Canadian dollars in revenue.
In section Market Quotes
Canopy Growth Trims Quarterly Losses as Canadian Cannabis Sales Climb
A 20 percent surge in cannabis revenue helped Canopy Growth narrow its fourth-quarter losses to 154.7 million Canadian dollars, a significant improvement from the 196 million Canadian dollars lost during the same period last year, even as the company missed broader quarterly revenue expectations by roughly 3 million Canadian dollars.
Looking toward fiscal 2027, leadership anticipates a trajectory of sustained growth. The company plans to leverage refined cultivation practices to bolster gross margins while maintaining strict control over operating expenses. Executives project the business will reach positive adjusted earnings before interest, taxes, depreciation, and amortization within the year, with profitability gains heavily concentrated in the second half of the fiscal calendar.
Comments (0)
No comments yet. Be the first!